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Introduction This study aimed to identify single nucleotide polymorphisms (SNPs) that are 
associated with outcome to treatment with sunitinib in patients with advanced GIST. 
Subjects and Methods  Forty-nine SNPS involved in the pharmacokinetic and pharmacodynamic 
pathway of sunitinib were associated with progression free survival (PFS) and overall survival (OS) in 
127 patients with advanced GIST who have been treated with sunitinib. 
Results and Discussion PFS was significantly longer in carriers of the TT-genotype in POR rs1056878 
(Hazard Ratio [HR] 4.310, 95%CI:1.457-12.746, p=0.008). The presence of the T-allele in SLCO1B3 
rs4149117 (HR 2.024, 95%CI:1.013-4.044, p=0.046), the CCC-CCC alleles in SLC22A5-haplotype (HR 
2.603, 95%CI:1.216-5.573, p=0.014), and the GC-GC alleles in the IL4R haplotype (HR 7.131, 
95%CI:1.518-33.496, p=0.013) were predictive for OS. This shows that polymorphisms in the 
pharmacokinetic and pharmacodynamic pathways of sunitinib are associated with survival in GIST. 












Since the introduction of imatinib as first line treatment for advanced gastrointestinal stromal 
tumors (GIST), progression free survival and overall survival of patients with this malignancy has 
dramatically improved. Unfortunately, eventually the vast majority of patients develop resistance to 
imatinib, mainly due to secondary mutations, while in others severe toxicity occurs, both resulting in 
the need to switch to second line treatment with sunitinib (Sutent; Pfizer Pharmaceuticals Group, 
New York, NY) (1). Sunitinib is a multi-targeted tyrosine kinase inhibitor (2, 3). Its clinical value in the 
treatment of patients with metastatic GIST has been shown in a randomized trial showing a median 
time to tumor progression of 27.3 weeks for patients treated with sunitinib, versus 6.4 weeks for 
patients treated with placebo (1). However, there is a large inter-individual difference in the efficacy 
of sunitinib in patients with GIST. This may in part be explained by the presence of specific mutations 
within the tumor (4) but another factor that may contribute to the variability in efficacy may be 
germline genetic variation. In patients treated with sunitinib for metastatic renal cell cancer, single 
nucleotide polymorphisms (SNPs) in genes related to the pharmacokinetic and pharmacodynamic 
pathways of sunitinib have been associated with outcome in terms of progression-free survival (PFS) 
and overall survival (OS) (5).  
In patients with GIST, the role of germline genetic polymorphisms as biomarkers predicting outcome 
has never been investigated. To further personalize treatment in this group of patients, it is 
meaningful to get better insight into the factors predicting the efficacy of a drug before starting, 
especially when alternative treatment options exist such as in the case of advanced GIST. Therefore, 
we performed a multicenter association analysis to explore whether polymorphisms in candidate 
genes within the pharmacokinetic or pharmacodynamic pathway of sunitinib are associated with PFS 





Study population and design 
From a large multicenter Dutch cohort of 365 patients with GIST, those patients who have been 
treated with second line sunitinib were selected. Patients had started sunitinib treatment between 
March 2004 and June 2014 in the Erasmus MC Cancer Institute, Leiden University Medical Center, 
Netherlands Cancer Institute – Antoni van Leeuwenhoek, or University Medical Center Groningen. 
Sunitinib could be administered in a 4 weeks on/2 weeks off treatment scheme, or in a continuous 
dosing regimen (or both), with any dose of sunitinib. Patients who have had dose reductions or dose 
escalations were allowed to be included in this study.  
Demographic data of patients was retrospectively collected in an electronic case record form, 
designed for this study. Collected patient characteristics were age, gender, self-declared ethnicity, 
Eastern Cooperative Oncology Group (ECOG) WHO performance score, weight, length, tumor 
characteristics (i.e. histology, mutation status, mitotic index (per 50 HPF), site of origin tumor, 
previous surgery), prior therapy and therapy after sunitinib, and survival estimates. For PFS and OS, 
data collection took place until August 2014.  
From each patient one sample of whole blood, serum or tumor surrounding tissue containing 
germline DNA was collected for DNA isolation. Samples could be either residuals or prospectively 
obtained samples in a study approved by the local medical ethical board. Samples were stored at -
20◦C or colder at the local hospital laboratory until further process. All samples were anonymized, 
according to the Codes for Proper use and Proper Conduct in the Self-Regulatory Codes of Conduct 
(www.federa.org). 
 
Genetic polymorphisms and haplotype estimation 
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Forty-nine SNP in 23 genes involved in the pharmacokinetics and pharmacodynamics of sunitinib 
were selected for genotyping, based on literature (see Table 1). SNPs were selected from the genes 
ABCB1, ABCC2, ABCG2, CYP1A1, CYP1A2, CYP3A4, NR1I2, NR1I3, POR (Cytochrome P450 
oxidoreductase), SLCO1B3, SLC22A1, SLC22A4 and SLC22A5 within the pharmacokinetic pathway and  
the genes FLT1, FLT3, IL-4R, IL-8, KDR (Kinase Insert Domain Receptor), PDGFRA, RET and VEGFA 
within the pharmacodynamic pathway. 
DNA isolation and genotyping were performed at the department of Clinical Pharmacy and 
Toxicology, Leiden University Medical Center. DNA was isolated from serum or whole blood using 
Magna Pure compact (Roche, Almere, the Netherlands), or from tumor surrounding tissue using 
Maxwell (Promega, Leiden, the Netherlands). DNA isolated from serum or tissue was pre-amplified 
as described before (6). 
SNPs were determined using the QuantStudio 12K Real-Time PCR System (Life Technologies, 
Bleiswijk, the Netherlands), with custom designed arrays. Custom designed pyrosequencing assays 
were used to enhance the call-rate above 90%. The mean genotype call-rate was 98.6% with a 
lowest call-rate of 93.2% and highest call-rate of 100%. The allele frequencies of seven out of 49 
SNPs were not in Hardy Weinberg equilibrium, but frequencies were comparable to the frequencies 
reported in the National Center for Biotechnology Information (NCBI) website 
(www.ncbi.nlm.nih.gov) and all SNPs were therefore kept within the analysis.  
SNPs within a gene were tested for linkage disequilibrium (LD) using Haploview (Broad Institute). 
Haplotypes were estimated for polymorphisms with an LD of more than 95%. The maximum 
likelihood estimates of haplotype probabilities were calculated using PLINK software, version 1.7 
(http://pngu.mgh.harvard.edu/purcell/plink/). Haplotype probabilities with a likelihood ≥95% were 
included in the statistical analysis. Haplotypes were formed from SNPs in NR1l3 (rs2307418, 
rs2307424, rs4073054), PDGFRA1 (rs1800810, rs1800812, rs1800813), PDGFRA2 (rs2228230, 
rs35597368), IL8 (rs1126647, rs4073), SLC22A5 (rs2631367, rs2631370, rs2631372), VEGFA 
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(rs2010963, rs699947, rs833061), IL4R (rs1801275, rs1805015). Separate statistical analyses were 
performed for the SNPs and the haplotypes. In case a haplotype contained a certain SNP that was 
significant, the analysis of the SNP was dropped. 
 
Statistics 
PFS was defined as the time between the first day of sunitinib treatment, and the day of progressive 
disease (PD), or death due to PD, whatever came first. If PD had not occurred in a patient, or in those 
cases where a patient was lost to follow-up, the patient was censored at the day of last follow-up. 
OS was defined as the time between the first day of sunitinib treatment and the date of death. 
Patients who had not died or of whom it was unknown whether they had died were censored at the 
last day of follow up.  
All SNPs and haplotypes were univariately tested against PFS and OS using the Kaplan-Meier method 
with the log-rank test. Patient characteristics were also univariately tested against PFS and OS, using 
either the Kaplan-Meier method with the log-rank test, or Cox regression analysis, based on the type 
of data. Variables and SNPs or haplotypes with a p-value ≤ 0.10 in the univariate analysis were 
selected for inclusion in a multivariate Cox-regression analysis, using PFS and OS as dependent 
variables. For SNPs, the best fitted model (multiplicative, wildtype dominant or mutant dominant 
based on genotype distribution) was chosen to enter into the multivariate analysis, based on the 
univariate analyses. Missing data from baseline characteristics that were associated with PFS or OS 
in the univariate analysis, were randomly imputed before entering the variable in the multivariate 
regression model. Depending on the variable, 1-40% of data was imputed. Multivariate analysis were 
performed twice, with and without replacement of missing variables. If results were similar in size 
and direction of effect, replacement was considered legitimate. 
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All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) version 
17.0 (SPSS, Chicago, IL). Given the explorative nature of this study, all results from multivariate 
analysis with p-value ≤ 0.05 were considered statistically significant and no correction for multiple 




The study population consisted of 127 patients with GIST treated with sunitinib, of whom 63% were 
men. The mean age at start of sunitinib was 61.2 ± 13.4 year. The stomach was the most frequent 
site of primary GIST location (38%). In fourteen patients (11%) a c-KIT exon 9 mutation was found, 
and 58 patients (46%) had a tumor with an exon 11 mutation in c-KIT in the primary tumor. Other 
mutations were found in c-KIT exon 13 (n = 2), exon 14 (n =1), exon 17 (n =2) or in PDGFR exon 18 (n 
= 7). In 43 patients (33.8%) the mutation in the primary tumor was unknown.  Most patients (76%) 
received sunitinib in an intermittent dosing scheme, starting sunitinib with 50 mg a day (n = 91, 72%) 
during the first 4 weeks, continued by 2 weeks off-dosing.  
At the time of analysis, 110 patients had stopped sunitinib treatment. In 87 patients (85%), this was 
because of PD and in all other cases because of severe toxicity. In the entire population, the median 
PFS was 7.6 months (interquartile range [IQR] 3.1-17.0 months) and the median OS was 18.3 months 
(IQR 9.7-29.3 months). The baseline characteristics of the study population are presented in Table 2.  
 
Pharmacogenetic biomarkers for PFS 
In the univariate analysis, PFS was longer for patients with the presence of the T-allele in KDR 
rs1870377 T/A (p = 0.033), the presence of the G-allele in IL13 rs20451 G/A (p = 0.025), the presence 
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of the C-allele in VEGFA rs25648 T/C (p = 0.014), and in the absence of 2 GCT copies in the VEGFA 
haplotype (p = 0.042) in the pharmacodynamic genes. With respect to the pharmacokinetic SNPs 
that were tested, the presence of the homozygous TT- allele in POR rs1057868 C/T (p = 0.008), and 
the absence of two CCC-copies in the SLC22A5 haplotype (p = 0.007) were univariately associated 
with prolonged PFS. From the baseline characteristics length (per cm increase HR 1.028; 95% CI: 
1.002-1.055, p = 0.032), mitotic index of the primary tumor (per cm increase HR 1.006, 95% CI: 
1.000-1.012, p = 0.042), age at start of sunitinib (per cm increase HR 0.986; 95% CI: 0.972-0.999, p = 
0.037) and the reason to stop imatinib (PD 13.7 months, other than PD 29.9 months;  p = 0.01) were 
included in the multivariate analysis.  
Only the homozygous TT genotype in POR rs1057868 C/T (HR 0.232, 95% CI: 0.078-0.686, p = 0.008) 
was associated with PFS in the multivariate Cox regression analysis (Table 3). A trend towards 
shorter PFS was seen for the presence of 2 copies of the CCC SLC22A5 haplotype, compared to 1 or 0 
copies (HR 2.358, 95% CI: 0.978-5.684, p = 0.056).  
 
Pharmacogenetic biomarkers for OS 
In the univariate analysis two pharmacodynamic SNPs within VEGFA were predictive for longer OS 
(rs1570360 G/A, absence of the A allele; p = 0.005 and rs699947 C/A, presence of the C-allele; p = 
0.036), as well as the presence of a CGG-copy in the PDGFRA1 haplotype (p = 0.007) and the 
presence of the GC-other or other-other alleles in the IL4R haplotype (p = 0.008). Within the 
pharmacokinetic pathway, the presence of the C-allele in ABCC2 rs717620 C/T (p = 0.006), as well as 
presence of the T-allele in SLCO1B3 rs4149117 G/T (p = 0.054). Two haplotypes within the 
pharmacokinetic pathway were associated with longer OS: the absence of 2 CTT-copies in NR1l3 (p < 
0.0001) and the absence of 2 CCC-copies in SLC22A5 (p = 0.001). 
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From the baseline characteristics that were univariately tested against OS, a better survival was seen 
in patients who stopped imatinib for another reason than PD (PD 25.8 months OS, other than PD 
55.4 months OS, p = 0.001), the absence of liver metastasis at start of sunitinib (44.2 vs 27.4 months, 
p = 0.093), and the absence of metastases at the time of diagnosis (37.6 vs 25.8 months OS, p = 
0.025). Multivariate Cox regression analysis showed SLCO1B3 rs4149117 G/T, the absence of a T-
allele (HR 2.024, 95% CI: 1.013-4.044, p = 0.046), the presence of 2 copies of the CCC SLC22A5 
haplotype (HR 2.603, 95% CI: 1.216-5.573, p = 0.014), and the presence of 2 copies of the GC IL4R 
haplotype (HR 7.131, 95% CI: 1.518-33.496, p = 0.013) as predictors for OS, as well as PD as a reason 
to stop imatinib (HR 3.025, 95% CI: 1.358-6.742, p = 0.007) and the presence of metastases at the 
time of the primary diagnosis GIST (HR 1.773, 95% CI: 1.044-3.012, p = 0.034). Data are presented in 
Table 4.  
 
Favorable genetic profile 
Polymorphisms and haplotypes that were significantly associated with OS (SLCO1B3 rs4149117 G/T, 
the presence of the T-allele, the absence of a CCC-copy in the SLC22A5 haplotype and the absence of 
a GC-copy in the IL4R haplotype) were combined in a favorable genetic profile for PFS and OS, using 
the number of favorable genetic factors.  
The number of favorable genetic factors was significantly associated with longer survival (PFS 9.2 vs 
15.6 vs 28.4 months for respectively one, two or three favorable genetic factors, p = 0.005). There 
was only 1 patient with no favorable genetic factors in our population. In a multivariate regression 
model including the clinical factors (reason to stop imatinib, length and mitotic index of the primary 
tumor), this was confirmed (HR 0.654, 95% CI 0.512-0.836, p = 0.001, Figure 1A). 
OS was significantly longer with an increasing number of positive predicting genetic factors (mean 
OS 16.0 vs 31.5 vs 49.5 months for respectively one, two or three positive predictive genetic factors, 
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p = 0.001). This was confirmed in a multivariate regression analysis, including the amount of 
favorable genetic factors and the clinical factors reason to stop imatinib, metastasis at primary 
diagnosis and liver metastasis at the start of sunitinib (HR 0.359, 95% CI 0.156-0.826, p = 0.016, 
Figure 1B). 
DISCUSSION 
Patients with GIST treated with sunitinib have a large inter-patient difference in PFS and OS. This 
may in part be explained by various tumor cell-related factors such as secondary mutations and by 
some clinical factors (4). However, genetic polymorphisms within the pharmacokinetic and 
pharmacodynamic pathways may add to this as they affect the exposure to and the efficacy of the 
drug, and thereby influence the outcome of treatment as well. In this explorative study we showed 
in a population of 129 patients with GIST, that polymorphisms in both the pharmacokinetic 
(SLCO1B3, SLC22A5 and POR) and the pharmacodynamic (IL4R) pathway of sunitinib are associated 
with PFS and OS in patients with advanced GIST treated with sunitinib.  
These findings indirectly suggest that survival to sunitinib in patients with GIST is subjected to 
exposure to sunitinib and its active metabolite. Sunitinib is metabolized by CYP3A4 and CYP3A5 into 
its active metabolite SU12662. This is converted to several inactive compounds by the same 
enzymes. The activity of cytochrome P450-enzymes is regulated by P450 oxydoreductase (POR). In 
our study, rs1056878, otherwise known as POR*28, was associated with prolonged PFS in sunitinib 
treated patients with GIST. Rs1056878 encodes for the amino acid variant A503V, and has been 
associated with lower activity of CYP1A2, CYP2D6, CYP3A5, but not of CYP3A4 (7). The finding that 
the polymorphic variant of rs1056878 is associated with better PFS suggests that carriers of this 
variant have a lower activity of metabolizing enzymes resulting in higher plasma concentrations. 
Sunitinib is a substrate of the ATP-binding cassette ABCB1 and ABCG2 efflux transporters, playing a 
role in both uptake and efflux of sunitinib. However, none of the SNPs in these genes were 
associated with survival in our analysis. The precise role of members of the organic cation 
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transporter novel (OCTN) family and the organic anion-transporting peptide (OATP) family in 
sunitinib absorption and elimination is unclear. However, SNPs in SLC22A5, which is the gene 
encoding for OCTN2, have been found to be associated with survival to imatinib in patients with GIST 
and CML (8). Interestingly, we found the SLC22A5 haplotype, consisting of rs2631367, rs2631370 
and rs2631372 to be significantly associated with longer OS. Carriers of the two CCC-copies had 
significantly shorter OS than patients with other allelic combinations. This is consistent with the 
finding in imatinib treated patients with GIST (8). Other member of the OCTN family that were 
tested in this study did not show a significant association with PFS or OS. In SLCO1B3, which encodes 
OATP1B3, rs4149117 was also associated with prolonged OS. Possibly, sunitinib is a substrate of 
these efflux transporters as well, but this needs to be elucidated. 
The homozygous GC-copy in the IL4R haplotype consisting of rs1801275, rs1805015 (Ser478Pro and 
Gln551Arg) was significantly associated with longer OS. In a previous study, SNPs in IL4R have been 
associated with the development of renal cell carcinoma (9). The finding that SNPs within IL4R are 
associated with OS in patients with GIST treated with sunitinib may be related to IL4R being involved 
in the tumor biology of GIST as well.  
A limitation of this study is that no pharmacokinetics of sunitinib as an intermediate endpoint were 
measured in this group of patients. Therefore, it can only be assumed that the effects of the SNPs on 
survival is caused by differences in pharmacokinetics. In a recent pharmacogenetic-pharmacokinetic 
study, CYP3A4*22 was found to have an effect size of > 20% on clearance (10). However, this finding 
was not statistically significant. 
Another limitation of this study is the sample size. Although this is the largest pharmacogenetic 
study in patients with GIST treated with sunitinib so far, the number of patients with specific 
genotypes is too small to draw conclusions from. Since this was an exploratory study, no formal 
correction for multiple testing was performed and results from the multivariate analyses with a p-
value less than 0.05 were considered significant. Currently, the False Discovery Rate (FDR) is 
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frequently used to control for reporting false positives in exploratory studies. Therefore, we 
calculated FDR values for each separate endpoint in a post-hoc analysis. FDR was below 10% for all 
SNPs with p<0.05 indicating a low likelihood of false positive findings.  
In our current study, SNP that were found associated with prolonged PFS, were not associated with 
OS and vice versa. This is somewhat surprising, since PFS and OS can be expected to be related to 
each other. However, while PFS only includes the effects of sunitinib treatment, OS also embodies 
the effects of any subsequent lines of treatment. Patients in our study received sunitinib over a 
broad area of time. In the first years after the registration of sunitinib, no good third line of 
treatment was available, but patients were frequently offered other treatment in the context of 
clinical studies. Since recently, regorafenib has been approved for third line treatment of GIST after 
failure of imatinib and sunitinib (11). This may have caused a bias in the overall survival in our 
analysis, as most patients did not receive this drug during earlier years. Still, we showed in a large 
group of patients that genetic polymorphisms can serve as a biomarker for overall survival. In one of 
our previous studies (5); studying polymorphisms associated with survival in RCC, a favorable genetic 
profile was found, including mutations in CYP3A5, NR1I3, and ABCB1. The only reason for the 
discrepancy with the current findings is the tumor type (GIST versus RCC).   
Progressive disease as the reason to stop imatinib treatment was univariately associated with both 
worsened PFS and worsened OS in our current study. In the multivariate analysis this was only 
confirmed for OS, but not for PFS. The existence of metastases at the time of the primary diagnosis 
was also associated with worse OS. Possibly, the tumor has a more aggressive behavior when 
metastasis are present at first diagnosis and when the tumor has already progressed on imatinib, 
rather than the patient switched to sunitinib for other reasons, resulting in shorter OS.  
Previously it has been described that primary mutations in c-KIT and PDGFRA may be predicting for 
the survival obtained by sunitinib in patients with GIST.  this was not seen in our study. This may be 
explained by the fact that all patients were pre-treated with imatinib. It has been shown that during 
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the treatment with imatinib, secondary mutations may arise, leading to imatinib-resistance (4). 
Therefore, mutations that are found in the primary tumor may not be representative of the 
mutations within the tumor after treatment with imatinib. Moreover, not in all tumor samples 
mutations in c-KIT and PDGFRA were determined. A lack of correlation between c-KIT and PDGFRA in 
univariate analysis may be (partly) due to missing data. 
Altogether we may conclude that polymorphisms in genes encoding for proteins related to the 
pharmacokinetic and pharmacodynamic pathways of sunitinib may be associated with survival in 
patients with GIST treated with sunitinib. When validated in the future, this may be useful to predict 
which patient is going to respond to sunitinib therapy, and which patients may better respond to 
other treatment types. 
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